Drugs / INSULIN GLARGINE/LIXISENATIDE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03529123 | Jun 2018 → Nov 2019 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INSULIN GLARGINE/LIXISENATIDE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03529123 ↗ |
| Known as | HOE901/AVE0010 | “INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)” NCT03529123 ↗ |
| Route | Subcutaneous | “Route of administration: Subcutaneous” NCT03529123 ↗ |